Skip to main content
Clinical Trials/NCT04950101
NCT04950101
Completed
Not Applicable

Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis

Universitair Ziekenhuis Brussel1 site in 1 country304 target enrollmentOctober 20, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Human Papilloma Virus
Sponsor
Universitair Ziekenhuis Brussel
Enrollment
304
Locations
1
Primary Endpoint
To determine the prevalence of anal high risk HPV infection in MSM using PrEP
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

The aim of the study is to determine the prevalence of anal high-risk HPV infection and abnormal cytology in HIV uninfected Men who have sex with men (MSM) using PrEP and HIV infected MSM followed-up at the S-kliniek or HRC of the UZ Brussel. 200 participants will be preferably included in the study. The data will be collected using a self-administered questionnaire where socio-demographic characteristics, health-related issues and sexual behavior will be questioned. Also anal canal sampling will be performed for cytological analysis. For the HIV infected MSM, additional information will be extracted from the patient files: CD4+ T-cell count and nadir and duration of combination antiretroviral therapy.

Registry
clinicaltrials.gov
Start Date
October 20, 2020
End Date
November 30, 2025
Last Updated
4 months ago
Study Type
Interventional
Study Design
Sequential
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • HIV uninfected MSM of 18 years or older using PrEP since at least 3 months
  • HIV-infected MSM of 18 years or older
  • Exclusion Criteria for MSM using PrEP:
  • Any intervention in the (peri-) anal region in the past 3 months
  • enema within 24h before sampling
  • receptive anal sex within 24h before sampling
  • current/ongoing peri-anal topical HPV-treatment
  • Exclusion Criteria for MSM infected with HPV:

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

To determine the prevalence of anal high risk HPV infection in MSM using PrEP

Time Frame: 2 year

Secondary Outcomes

  • To compare the prevalence of high risk HPV in MSM using PrEP with that of HIV uninfected MSM not using PrEP(2 year)
  • To compare the prevalence of high risk HPV in MSM using PrEP with that of HIV infected MSM(2 year)
  • to determine the prevalence of abnormal anal cytology in MSM using PrEP and in HIV infected MSM(2 year)

Study Sites (1)

Loading locations...

Similar Trials